The LACOG-0415 phase II trial: abirateroneacetate and ADT versus apalutamide versusabiraterone acetate and apalutamide inpatients with advanced prostate cancerwith non-castration testosterone levels
Gustavo Werutsky, Fernando Cotait Maluf, Eduardo Henrique Cronemberger, Vinicius Carrera Souza, Suelen Patricia dos Santos Martins, Fábio Peixoto, Oren Smaletz, Fábio Schutz, Daniel Herchenhorn, Telma Santos, Flavio Mavignier Carcano, David Queiroz Muniz, Paulo R. S. Nunes Filho, Facundo Zaffaroni, Carlos Barrios and André Fay BMC Cancer
Phase II randomized study of Abiraterone acetate plus ADT versus ARN 509 versus Abiraterone and ARN 509 in patients with advanced prostate cancer with non-castrate testosterone levels.
Fernando Maluf, Oren Smaletz, Fabio Schutz, Vinicius Carrera Souza, Andre Poisl Fay, Daniel Herchenhorn, Gustavo Werutsky, Telma Murias Santos ASCO GU 2018 Full link: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.6_suppl.TPS404#affiliationsContainer